- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03827863
Acute CorPulmonale and ARDS Circulation Protection China Study China (ACPC)
The Prospective Observational Study of ARDS Related Acute CorPulmonale and the Randomized Controlled Study of ARDS Aimed Circulation Protection China (ACPC)
The investigators established a national cohort of Chinese ARDS with Acute CorPulmonale to enable prospective observational studies. The goals are the following.
First, morbidity and mortality rate of ARDS with ACP in the ICU across Chinese mainland.
Second, forming the diagnostic ultrasound strategy of ARDS-ACP, namely TRIP procedures. And predictive value of diagnostic strategy for ACP or prognosis of ACP were calculated.
Third, comparison of ventilator parameters for ACP and non-ACP or survivor and non-survisors, which reaveald that of inappropriate mechanical ventilation on circulation and prognosis. Screening for risk factors of ARDS with ACP.
Study Overview
Status
Intervention / Treatment
Detailed Description
Acute respiratory distress syndrome (ARDS) is an acute and critical illness characterized by progressive dyspnea and refractory hypoxemia caused by intrapulmonary or extrapulmonary factors. The mortality rate of ARDS is extremely high. ACP caused by pulmonary circulatory disorder is its main clinical feature, which is related to the severity of lung injury in ARDS patients. It has been recognized that the ACP is an independent risk factor for the prognosis of patients with ARDS. Positive pressure mechanical ventilation is an important ARDS treatment strategy for ARDS. Especially the lung protective ventilation strategy with "small tidal volume and increased PEEP" as the core content, which achieved a milestone of lower the mortality of ARDS. However, improper use of positive pressure mechanical ventilation can increase right ventricular load and increase mortality in ARDS patients. Therefore, understanding the effect of positive pressure mechanical ventilation on right heart function in patients with ARDS is important for prevention and treatment for the ACP of ARDS and reduction of ARDS mortality.
The alveolar edema, alveolar collapse, and hypoxic pulmonary vasoconstriction loss caused by increased pulmonary vascular permeability and release of inflammatory mediators resulted in loss of ventilation/blood flow, severe hypoxemia, pulmonary vasospasm, pulmonary microthrombus formation, which increased pulmonary arterial pressure and even APC. Positive pressure mechanical ventilation maintains alveolar ventilation through positive airway pressure, prevents premature alveolar collapse by positive end expiratory pressure (PEEP), changes intrathoracic pressure and lung volume, and affects the right ventricle load. Different studies have found that the incidence of ACP in patients with ARDS is from 22% to 60%. Jardin, et al found that patients with ARDS had a significant increase in ACP and mortality when the airway pressure was greater than 26 cmH2O, which revealed that the difference in positive pressure mechanical ventilation settings has a significant difference in the right heart function of ARDS patients. Mekontso, et al propose a simple clinical risk score for early identification of ACP included pneumonia as cause of ARDS, driving pressure ≥18cmH2O, PaO2/FiO2 ratio<150 mmHg, and PaCO2≥48mmHg. However, for the morbidity and mortality of ACP in ARDS, the related risk factors and criteria are different due to the influence of the different etiology of ARDS and the different study time. For these reasons, the investigators established a national cohort of Chinese ARDS with Acute CorPulmonale to enable prospective observational studies.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100730
- Peking Union Medical College Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18≤ aged ≤85 years old
- received a diagnosis of ARDS with Acute CorPulmonal
- provided signed informed consent
Exclusion Criteria:
- are diagnosed as cardiogenic pulmonary edema
- are diagnosed as Idiopathic pulmonary fibrosis acute exacerbation
- are participating in other interventional clinical trials
- refused to continue to participate in the study or refused further treatment
- unable to complete the study procedure even if assisted and otherwise unable to comply with the study protocol
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
ARDS WITH ACP
|
TTE to detect the heart function
|
|
ARDS WITHOUT ACP
Diagnosis as ARDS but no ultrasound evidence of ACP.
|
TTE to detect the heart function
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
28 days SURVIVAL
Time Frame: 28 days after ICU admission
|
28 days after ICU admission
|
|
length of stay of ICU
Time Frame: 1 years
|
1 years
|
|
mechanical ventilation time
Time Frame: 1 years
|
1 years
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS-1615
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ARDS (Acute Respiratory Distress Syndrome)
-
New York UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Fundacion del Hospital Nacional de Paraplejicos...Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)Spain
-
Jee Hwan AhnNot yet recruitingAcute Respiratory Distress Syndrome (ARDS)South Korea
-
Southeast University, ChinaJiangsu Province Hospital of Traditional Chinese Medicine; The First Affiliated... and other collaboratorsNot yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Zhongda HospitalRecruitingAcute Respiratory Distress Syndrome (ARDS)China
-
Assistance Publique - Hôpitaux de ParisRecruitingAcute Respiratory Distress Syndrome (ARDS)France
-
EnliTISA (Shanghai) Pharmaceutical Co., Ltd.CompletedAcute Respiratory Distress Syndrome (ARDS)China
-
Fayoum UniversityNot yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Ain Shams UniversityRecruitingAcute Respiratory Distress Syndrome (ARDS)Egypt
Clinical Trials on TTE
-
Tianjin Chest HospitalRecruitingCoronary Artery Disease | Stable Angina Pectoris | Major Adverse Cardiac Events | Invasive Coronary Angiography | Transthorcic EchocardiographyChina
-
Rijnstate HospitalNot yet recruitingCardiac Output, Low
-
Philipps University Marburg Medical CenterKerckhoff Heart CenterCompletedHemodynamic Instability During Anesthesia | High Risk SurgeryGermany
-
Luzerner KantonsspitalUnknownCoronary Disease | Aortic Valve StenosisSwitzerland
-
Centre Hospitalier Universitaire, AmiensRecruitingThoracic Surgery | Right VentricleFrance
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruitingAortic Regurgitation | Transcatheter Aortic Valve Replacement (TAVR)
-
NovaSignal Corp.CompletedTransient Ischemic Attack | Patent Foramen Ovale | Embolic Stroke of Undetermined Source | Right-To-Left Atrial ShuntUnited States
-
Metanoic Health Ltd.Abbott Medical DevicesCompletedMitral Regurgitation | Acute Heart FailureUnited Kingdom
-
Lawson Health Research InstituteCompletedDelirium | Arthroplasty, Replacement, Knee | Foramen Ovale, Patent | Arthroplasty, Replacement, HipCanada
-
Ayman khairy MohamedCompletedAtrial Septal Defect, Secundum TypeEgypt